vs
Side-by-side financial comparison of Rexford Industrial Realty, Inc. (REXR) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $245.1M, roughly 1.2× Rexford Industrial Realty, Inc.). Bio-Techne runs the higher net margin — 12.8% vs 0.5%, a 12.3% gap on every dollar of revenue. On growth, Rexford Industrial Realty, Inc. posted the faster year-over-year revenue change (-2.9% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs 1.6%).
Genpact Ltd. is an American information technology services, consulting, and outsourcing company headquartered in New York City, New York. Founded in Gurgaon, India, and legally domiciled in Bermuda, Genpact employs more than 125,000 people and provides services to clients in over 30 countries worldwide. Genpact is listed on the NYSE and generated revenues of US$4.48 billion in 2023.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
REXR vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $245.1M | $295.9M |
| Net Profit | $1.2M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | 41.0% | 18.4% |
| Net Margin | 0.5% | 12.8% |
| Revenue YoY | -2.9% | -6.4% |
| Net Profit YoY | 27.7% | 68.3% |
| EPS (diluted) | $0.38 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $245.1M | — | ||
| Q4 25 | $248.1M | $295.9M | ||
| Q3 25 | $253.2M | — | ||
| Q2 25 | $249.5M | $317.0M | ||
| Q1 25 | $252.3M | $316.2M | ||
| Q4 24 | $242.9M | $297.0M | ||
| Q3 24 | $241.8M | $289.5M | ||
| Q2 24 | $237.6M | $306.1M |
| Q1 26 | $1.2M | — | ||
| Q4 25 | — | $38.0M | ||
| Q3 25 | $89.9M | — | ||
| Q2 25 | $116.3M | $-17.7M | ||
| Q1 25 | $71.2M | $22.6M | ||
| Q4 24 | $64.9M | $34.9M | ||
| Q3 24 | $67.8M | $33.6M | ||
| Q2 24 | $82.5M | $40.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | 41.0% | — | ||
| Q4 25 | — | 18.4% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -7.5% | ||
| Q1 25 | — | 12.2% | ||
| Q4 24 | — | 16.0% | ||
| Q3 24 | — | 13.8% | ||
| Q2 24 | — | 15.0% |
| Q1 26 | 0.5% | — | ||
| Q4 25 | — | 12.8% | ||
| Q3 25 | 35.5% | — | ||
| Q2 25 | 46.6% | -5.6% | ||
| Q1 25 | 28.2% | 7.1% | ||
| Q4 24 | 26.7% | 11.7% | ||
| Q3 24 | 28.0% | 11.6% | ||
| Q2 24 | 34.7% | 13.3% |
| Q1 26 | $0.38 | — | ||
| Q4 25 | — | $0.24 | ||
| Q3 25 | $0.37 | — | ||
| Q2 25 | $0.48 | $-0.11 | ||
| Q1 25 | $0.30 | $0.14 | ||
| Q4 24 | $0.26 | $0.22 | ||
| Q3 24 | $0.30 | $0.21 | ||
| Q2 24 | $0.37 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $51.7M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $8.3B | $2.0B |
| Total Assets | $12.4B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $51.7M | — | ||
| Q4 25 | $165.8M | $172.9M | ||
| Q3 25 | $249.0M | — | ||
| Q2 25 | $431.1M | $162.2M | ||
| Q1 25 | $504.6M | $140.7M | ||
| Q4 24 | $56.0M | $177.5M | ||
| Q3 24 | $61.8M | $187.5M | ||
| Q2 24 | $125.7M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | $3.3B | $260.0M | ||
| Q3 25 | $3.2B | — | ||
| Q2 25 | $3.3B | $346.0M | ||
| Q1 25 | $3.3B | $330.0M | ||
| Q4 24 | $3.3B | $300.0M | ||
| Q3 24 | $3.4B | $300.0M | ||
| Q2 24 | $3.3B | $319.0M |
| Q1 26 | $8.3B | — | ||
| Q4 25 | $8.5B | $2.0B | ||
| Q3 25 | $8.7B | — | ||
| Q2 25 | $8.8B | $1.9B | ||
| Q1 25 | $8.8B | $2.0B | ||
| Q4 24 | $8.3B | $2.1B | ||
| Q3 24 | $8.1B | $2.1B | ||
| Q2 24 | $8.0B | $2.1B |
| Q1 26 | $12.4B | — | ||
| Q4 25 | $12.6B | $2.5B | ||
| Q3 25 | $12.9B | — | ||
| Q2 25 | $13.1B | $2.6B | ||
| Q1 25 | $13.1B | $2.6B | ||
| Q4 24 | $12.6B | $2.7B | ||
| Q3 24 | $12.4B | $2.7B | ||
| Q2 24 | $12.4B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | 0.38× | 0.13× | ||
| Q3 25 | 0.37× | — | ||
| Q2 25 | 0.38× | 0.18× | ||
| Q1 25 | 0.38× | 0.16× | ||
| Q4 24 | 0.40× | 0.14× | ||
| Q3 24 | 0.42× | 0.14× | ||
| Q2 24 | 0.42× | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
REXR
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
